How Roche is finding better ways to diagnose brain conditions like Alzheimer’s and Parkinson’s disease

“[Cardiology] has had good diagnostic tests and highly efficacious drugs for 30 years, but in the neurology spaces, especially in Alzheimer’s, drugs are only just starting to make it through,” said Bruce Jordan, international business leader for personalized healthcare solutions in neurology and general medicine at Roche. “There are a huge number of gaps in the markets around the world in terms of the availability of good, dependable biomarkers that can be run on in vitro diagnostic analyzers.”